Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: scion who wrote (114034)	3/6/2012 8:21:07 AM
From: scion	Respond to of 122087

Ex-F.D.A. Chemist Sentenced to 5 Years in Insider Case March 5, 2012, 7:52 pm By PETER LATTMAN dealbook.nytimes.com A federal judge sentenced a longtime chemist with the Food and Drug Administration to five years in prison for using confidential information about drug applications pending with the agency to make nearly $4 million in illegal trading profits. Cheng Yi Liang, the chemist, was sentenced by Judge Deborah K. Chasanow on Monday in federal court in Maryland after he had pleaded guilty last year to insider trading crimes. Federal authorities arrested him and his son, Andrew Liang, last March. “Taking advantage of his special access as a chemist at the F.D.A., Mr. Liang used sensitive inside information to reap illegal profits in the pharmaceutical securities market,” Lanny A. Breuer, the assistant attorney general of the Justice Department’s criminal division, said in a statement. “For years, he exploited his position in the agency to make easy money on the stock market. But today’s sentence shows that easy money has consequences. Investors engage in insider trading at their peril.” The case brought against Mr. Laing was a rare prosecution of an official from the F.D.A., an agency that handles a large amount of market-moving information. The agency has a rigorous ethics code and imposes significant trading restrictions on its employees. The five-year sentence was at the low-end of the 57- to 71-month range suggested by the nonbinding federal sentencing guidelines. Mr. Liang used the F.D.A.’s internal databases to gather information about upcoming agency announcements and then would buy stock of companies that he knew were due for positive news from F.D.A. reports or would sell short companies he knew were going to receive negative news. He would then close out his positions after the F.D.A. released its verdict on drug applications. For instance, Mr. Liang traded in advance of a May 2009 announcement by Vanda Pharmaceuticals that the F.D.A. had approved its drug Fanapt. Using several brokerage accounts, Mr. Liang and his son reaped more than $1 million in profit, for a nearly 800 percent profit. Mr. Liang, 58, agreed to forfeit more than $3.7 million in illegal earnings, including his home in Gaithersburg, Md. His son had previously pleaded guilty and was sentenced to a year in prison. The younger Mr. Liang was also charged with possession of child pornography and had to register as a sex offender. Separately, Mr. Breuer is receiving an award on Monday night at the 37th annual dinner of the Hogan-Morgenthau Associates, which is a group of alumni who served in the New York district attorney’s office under the two former district attorneys, Frank S. Hogan and Robert M. Morgenthau. He and Ron Reich, the assistant attorney general for the office of legislative affairs, are joint recipients of the award. This post has been revised to reflect the following correction: Correction: March 6, 2012 Robert M. Morgenthau's last name was misspelled in an earlier version of this article. dealbook.nytimes.com